Charles N. York II Sells 4,282 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 4,282 shares of the firm’s stock in a transaction on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the sale, the chief financial officer now directly owns 265,231 shares of the company’s stock, valued at approximately $1,660,346.06. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Day One Biopharmaceuticals Trading Up 3.7%

NASDAQ DAWN traded up $0.23 during trading on Monday, reaching $6.48. 1,811,522 shares of the company’s stock were exchanged, compared to its average volume of 1,107,801. The firm has a market capitalization of $656.83 million, a PE ratio of -6.29 and a beta of -1.24. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $6.08 and a fifty-two week high of $16.76. The company’s fifty day simple moving average is $7.44 and its 200-day simple moving average is $10.77.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its earnings results on Tuesday, May 6th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.11. The firm had revenue of $30.76 million during the quarter, compared to analysts’ expectations of $30.28 million. Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at approximately $27,000. R Squared Ltd bought a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Quantbot Technologies LP bought a new stake in shares of Day One Biopharmaceuticals in the first quarter valued at approximately $82,000. Pallas Capital Advisors LLC acquired a new stake in shares of Day One Biopharmaceuticals in the first quarter worth $87,000. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Day One Biopharmaceuticals during the first quarter worth $88,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. The Goldman Sachs Group reduced their target price on Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, March 25th. JPMorgan Chase & Co. reduced their price objective on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a research note on Wednesday, March 5th. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, May 7th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. Finally, Needham & Company LLC reduced their price target on shares of Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $30.57.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.